Skip to content
10-Q/A

Quarterly Report

MAP PHARMACEUTICALS, INC.

0001193125-12-143565

← back to feed
Filed
Mar 30, 2012 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2011 · Oct 31, 2011 30.5M sh
Shares Diluted Q3 2011 · Sep 30, 2011 31.61M sh
Shares Diluted restated Q3 2011 · Sep 30, 2011 30.33M sh
Shares Diluted Q3 2011 · Sep 30, 2010 26.63M sh
Shares Diluted Q3 2011 · Sep 30, 2010 26.32M sh
Capex restated Q3 2011 · Sep 30, 2011 $911K
Capex Q3 2011 · Sep 30, 2011 $12.43M
Capex Q3 2011 · Sep 30, 2010 $1.98M
Operating Cash Flow restated Q3 2011 · Sep 30, 2011 $40.92M
Operating Cash Flow Q3 2011 · Sep 30, 2011 −$150.72M
Operating Cash Flow Q3 2011 · Sep 30, 2010 −$37.93M
Short Term Debt Q3 2011 · Sep 30, 2011 $1.69M
Short Term Debt Q3 2011 · Dec 31, 2010 $7.58M
Cash And Equivalents Q3 2011 · Sep 30, 2011 $111.84M
Cash And Equivalents Q3 2011 · Dec 31, 2010 $76.01M
Cash And Equivalents Q3 2011 · Sep 30, 2010 $41.82M
Cash And Equivalents Q3 2011 · Dec 31, 2009 $65.78M
Stockholders Equity restated Q3 2011 · Sep 30, 2011 $50.81M
Stockholders Equity Q3 2011 · Dec 31, 2010 $62.66M
Current Liabilities restated Q3 2011 · Sep 30, 2011 $13.65M
Current Liabilities Q3 2011 · Dec 31, 2010 $20.02M
Total Liabilities restated Q3 2011 · Sep 30, 2011 $68.07M
Total Liabilities Q3 2011 · Dec 31, 2010 $20.14M
Current Assets Q3 2011 · Sep 30, 2011 $112.76M
Current Assets Q3 2011 · Dec 31, 2010 $76.65M
Total Assets Q3 2011 · Sep 30, 2011 $118.88M
Total Assets Q3 2011 · Dec 31, 2010 $82.79M
Eps Diluted restated Q3 2011 · Sep 30, 2011 $0.26
Eps Diluted restated Q3 2011 · Sep 30, 2011 −$0.63
Eps Diluted Q3 2011 · Sep 30, 2010 −$0.53
Eps Diluted Q3 2011 · Sep 30, 2010 −$1.55
Eps Basic restated Q3 2011 · Sep 30, 2011 $0.27
Eps Basic restated Q3 2011 · Sep 30, 2011 −$0.63
Eps Basic Q3 2011 · Sep 30, 2010 −$0.53
Eps Basic Q3 2011 · Sep 30, 2010 −$1.55
Sga Expense Q3 2011 · Sep 30, 2011 $5.89M
Sga Expense Q3 2011 · Sep 30, 2011 $15.53M
Sga Expense Q3 2011 · Sep 30, 2011 $78.44M
Sga Expense Q3 2011 · Sep 30, 2010 $3.92M
Sga Expense Q3 2011 · Sep 30, 2010 $11.71M
Rd Expense Q3 2011 · Sep 30, 2011 $6.73M
Rd Expense Q3 2011 · Sep 30, 2011 $25.55M
Rd Expense Q3 2011 · Sep 30, 2011 $243.02M
Rd Expense Q3 2011 · Sep 30, 2010 $10.01M
Rd Expense Q3 2011 · Sep 30, 2010 $28.04M
Net Income restated Q3 2011 · Sep 30, 2011 $8.18M
Net Income restated Q3 2011 · Sep 30, 2011 −$19.12M
Net Income restated Q3 2011 · Sep 30, 2011 −$246.67M
Net Income Q3 2011 · Sep 30, 2010 −$14.18M
Net Income Q3 2011 · Sep 30, 2010 −$40.73M
Operating Income restated Q3 2011 · Sep 30, 2011 $8.22M
Operating Income restated Q3 2011 · Sep 30, 2011 −$18.85M
Operating Income restated Q3 2011 · Sep 30, 2011 −$245.07M
Operating Income Q3 2011 · Sep 30, 2010 −$13.93M
Operating Income Q3 2011 · Sep 30, 2010 −$39.75M
Revenue restated Q3 2011 · Sep 30, 2011 $20.84M
Revenue restated Q3 2011 · Sep 30, 2011 $22.23M
Revenue restated Q3 2011 · Sep 30, 2011 $76.4M